Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
21.38 ^USD	-1.02%		-10.54%	-21.45%

Apr. 04	Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	MT
Apr. 04	Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	MT

Beam Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 08, 2023 at 07:31 am EST

Beam Therapeutics Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 96.09 million compared to USD 109.58 million a year ago. Basic loss per share from continuing operations was USD 1.22 compared to USD 1.56 a year ago.
For the nine months, net loss was USD 275.32 million compared to USD 250.74 million a year ago. Basic loss per share from continuing operations was USD 3.63 compared to USD 3.59 a year ago.

Latest news about Beam Therapeutics Inc.

Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	Apr. 04	MT
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	Apr. 04	MT
Beam Therapeutics Says BEAM-302 Drug Candidate Gets UK Clearance for Alpha-1 Antitrypsin Deficiency	Mar. 26	MT
Beam Therapeutics Inc. Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency	Mar. 26	CI
Transcript : Beam Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:35 PM	Mar. 13
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating	Feb. 28	MT
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk	Feb. 28	MT
Health Care Down as Viking Move Rattles Novo Shares -- Health Care Roundup	Feb. 27	DJ
Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating	Feb. 27	MT
Beam Therapeutics Shares Jump on Surprise Q4 Profit	Feb. 27	MT
Beam Therapeutics Reports Surprise Q4 Profit; Shares Jump in Early Trading	Feb. 27	MT
Beam Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto	Jan. 30	MT
North American Morning Briefing : Microsoft Kicks -2-	Jan. 30	DJ
Beam Therapeutics Shares Gain Following JPMorgan's Upgrade to Overweight	Jan. 29	MT
JPMorgan Upgrades Beam Therapeutics to Overweight From Neutral, Raises Price Target to $40 From $38	Jan. 29	MT
Transcript : Beam Therapeutics Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 11:15 AM	Jan. 08
Beam Therapeutics Inc. Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones	Jan. 08	CI
North American Morning Briefing : Stock Futures -2-	Dec. 18	DJ
BofA Securities Downgrades Beam Therapeutics to Neutral From Buy, Price Target is $35	Dec. 15	MT
Beam Therapeutics Inc. Appoints Christi Shaw to Its Board of Directors	Dec. 14	CI
North American Morning Briefing : Investors Await -2-	Dec. 11	DJ
Jefferies Downgrades Beam Therapeutics to Hold From Buy, Cuts Price Target to $30 From $75	Dec. 08	MT
Beam Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
North American Morning Briefing : Stocks Look to -2-	Nov. 06	DJ

Chart Beam Therapeutics Inc.

Duration

Period

More charts

Company Profile

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto

January 30, 2024 at 02:21 pm EST

More Strategies

Ratings for Beam Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

21.38 USD

Average target price

49.54 USD

Spread / Average Target

+131.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BEAM THERAPEUTICS INC.	-21.45%	1.7B
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research